Lundin Law PC (http://lundinlawpc.com/) announces it is investigating claims against CytRx Corporation (“CytRx” or the “Company”) (Nasdaq: CYTR) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.
No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the July 12, 2016 disclosure of the results of the Company’s Phase 3 clinical trial of aldoxorubicin, which did not show any improvement from other commonly used cancer drugs. CytRX stated that almost half of the patients in the Phase 3 trial were excluded from the data since the study was disturbed by a partial clinical hold on November 2014. When this news was revealed, stock prices fell sharply.
Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160725006176/en/
Contacts:
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile:
888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/
